Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
Clarithromycin v Ciprofloxacin Added to Rifampicin + Ethambutol, for Opportunist Mycobacterial Pulmonary Disease
To date key drugs in the treatment of MAIS, M.malmoense and M.xenopi (Opportunist
 Mycobacteria have been rifampicin and ethambutol. Clarithromycin and Ciprofloxacin are active
 in vitro against these species of mycobacteria. The primary aim of this study was to compare
 these to agents as supplements to rifampicin and ethambutol. A secondary aim was to assess
 the vale of immunotherapy with M.vaccae.
Inclusion Criteria:

 -  Patients with pulmonary disease due to M.avium intracellulare, M.malmoense or
 M.xenopi. Aged 16 or over. With clinical and/or radiological evidence of active
 infection and producing sputum positive on culture on at least 2 occasions.

 Exclusion Criteria:

 -  Pregnant women and women of childbearing age not taking adequate contraceptive
 precautions.

 Patients who have sputum currently positive on culture for M.tuberculosis or M.bovis.

 Patients who have AIDS or who are known to be HIV positive